H Nakamura1, H Tanaka, S Yoshino. 1. Institute of Medical Science, St. Marianna University, Kanagawa, Japan. nakamura@marianna-u.ac.jp
Abstract
OBJECTIVES: We developed a radical multiple synovectomy (RaMS) procedure designed to reduce disease activity in refractory RA patients involving the excision of all inflamed synovial tissues. In this study we examined the long-term outcome of RaMS in terms of disease activity and articular destruction. METHODS: Forty-two patients with refractory RA underwent RaMS and were followed up for an average of 7.3 years. Clinical findings and radiological outcome were evaluated and compared to a control group. RESULTS: More than 40% of patients continued to maintain improvement up to 4 years after the operation. The number of swollen joints and painful joints, the erythrocyte sedimentation rate, CRP and rheumatoid factor quickly decreased after the operation. The beneficial effects continued for 4 years compared to patients treated with combination disease modifying anti-rheumatic drug therapy. The damage score worsened less rapidly in patients undergoing RaMS than in the control group. Articular destruction was less marked in the PIP, MP, wrist and ankle joints of patients who responded well to RaMS. CONCLUSIONS: RaMS was effective for refractory RA in the short term and seemed to offer some advantages over other therapies in terms of slowing articular destruction. However, RaMS did not radically alter the natural disease course of RA.
OBJECTIVES: We developed a radical multiple synovectomy (RaMS) procedure designed to reduce disease activity in refractory RApatients involving the excision of all inflamed synovial tissues. In this study we examined the long-term outcome of RaMS in terms of disease activity and articular destruction. METHODS: Forty-two patients with refractory RA underwent RaMS and were followed up for an average of 7.3 years. Clinical findings and radiological outcome were evaluated and compared to a control group. RESULTS: More than 40% of patients continued to maintain improvement up to 4 years after the operation. The number of swollen joints and painful joints, the erythrocyte sedimentation rate, CRP and rheumatoid factor quickly decreased after the operation. The beneficial effects continued for 4 years compared to patients treated with combination disease modifying anti-rheumatic drug therapy. The damage score worsened less rapidly in patients undergoing RaMS than in the control group. Articular destruction was less marked in the PIP, MP, wrist and ankle joints of patients who responded well to RaMS. CONCLUSIONS: RaMS was effective for refractory RA in the short term and seemed to offer some advantages over other therapies in terms of slowing articular destruction. However, RaMS did not radically alter the natural disease course of RA.
Authors: Myew-Ling Toh; Gaelle Gonzales; Marije I Koenders; Anne Tournadre; David Boyle; Erik Lubberts; Yuan Zhou; Gary S Firestein; Wim B van den Berg; Pierre Miossec Journal: PLoS One Date: 2010-10-15 Impact factor: 3.240
Authors: Huub J L van der Heide; Bernard Schutte; Jan Willem K Louwerens; Frank H J van den Hoogen; Maarten C de Waal Malefijt Journal: Acta Orthop Date: 2009-08 Impact factor: 3.717